Affinity Asset Advisors
Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, APGE, INSM, ABVX, IBB, and represent 27.92% of Affinity Asset Advisors's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$183M), IBB (+$68M), PRAX (+$55M), AMGN (+$48M), XLV (+$39M), CYTK (+$29M), FBRX (+$28M), VTYX (+$23M), TERN (+$22M), ANAB (+$22M).
- Started 26 new stock positions in AVBP, XFOR, XBI, RCUS, AVDL, LENZ, VRCA, Cogent Biosciences, FBRX, TERN.
- Reduced shares in these 10 stocks: VRNA (-$67M), , MDGL (-$49M), INSM (-$36M), MRUS (-$27M), , SLNO (-$14M), CNTA (-$13M), Karyopharm Therapeutics Inc note 3.000%10/1 (-$13M), ELVN (-$8.2M).
- Sold out of its positions in ATYR, AKBA, Astria Therapeutics, AUTL, CNTX, ELVN, EXEL, INSP, NTLA, Karyopharm Therapeutics Inc note 3.000%10/1.
- Affinity Asset Advisors was a net buyer of stock by $313M.
- Affinity Asset Advisors has $1.8B in assets under management (AUM), dropping by 52.88%.
- Central Index Key (CIK): 0001773195
Tip: Access up to 7 years of quarterly data
Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Affinity Asset Advisors
Affinity Asset Advisors holds 92 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Series Trust State Street Spd Put Option (XBI) | 10.4 | $183M | NEW | 1.5M | 121.93 |
|
| Apogee Therapeutics (APGE) | 5.3 | $93M | +5% | 1.2M | 75.48 |
|
| Insmed Com Par $.01 (INSM) | 4.5 | $78M | -31% | 450k | 174.04 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.9 | $68M | +40% | 505k | 134.85 |
|
| Ishares Tr Ishares Biotech Call Option (IBB) | 3.8 | $68M | NEW | 400k | 168.77 |
|
| Ventyx Biosciences (VTYX) | 3.3 | $59M | +65% | 6.5M | 9.03 |
|
| Xenon Pharmaceuticals (XENE) | 3.2 | $56M | -10% | 1.3M | 44.82 |
|
| Praxis Precision Medicines I Com New (PRAX) | 3.1 | $55M | NEW | 185k | 294.74 |
|
| Cytokinetics Com New (CYTK) | 2.9 | $51M | +128% | 800k | 63.54 |
|
| Amgen (AMGN) | 2.7 | $48M | NEW | 145k | 327.31 |
|
| Spyre Therapeutics Com New (SYRE) | 2.7 | $47M | 1.4M | 32.76 |
|
|
| Wave Life Sciences SHS (WVE) | 2.6 | $46M | +28% | 2.7M | 17.00 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 2.5 | $44M | 1.4M | 31.21 |
|
|
| Select Sector Spdr Tr State Street Hea Call Option (XLV) | 2.2 | $39M | NEW | 250k | 154.80 |
|
| Roivant Sciences SHS (ROIV) | 2.1 | $37M | +112% | 1.7M | 21.70 |
|
| Arcellx Common Stock (ACLX) | 1.9 | $34M | +4% | 524k | 65.20 |
|
| Nuvalent Inc-a (NUVL) | 1.8 | $33M | -16% | 323k | 100.59 |
|
| Lexeo Therapeutics (LXEO) | 1.8 | $32M | -17% | 3.2M | 9.93 |
|
| Alkermes SHS (ALKS) | 1.6 | $28M | -20% | 1.0M | 27.98 |
|
| Forte Biosciences Com New (FBRX) | 1.6 | $28M | NEW | 1.0M | 27.27 |
|
| Trevi Therapeutics (TRVI) | 1.5 | $27M | -23% | 2.2M | 12.52 |
|
| Mineralys Therapeutics (MLYS) | 1.5 | $27M | -2% | 730k | 36.29 |
|
| Bridgebio Pharma (BBIO) | 1.4 | $25M | +392% | 320k | 76.49 |
|
| Oruka Therapeutics (ORKA) | 1.4 | $24M | -16% | 802k | 30.31 |
|
| Terns Pharmaceuticals (TERN) | 1.3 | $22M | NEW | 550k | 40.40 |
|
| Anaptysbio Inc Common (ANAB) | 1.2 | $22M | NEW | 445k | 48.48 |
|
| Uniqure Nv SHS (QURE) | 1.2 | $20M | +183% | 850k | 23.93 |
|
| Cullinan Oncology (CGEM) | 1.1 | $20M | +632% | 1.9M | 10.35 |
|
| Omeros Corp Note 9.500% 6/1 (Principal) | 1.1 | $19M | +18% | 6.5M | 2.97 |
|
| Avalo Therapeutics Com New (AVTX) | 1.1 | $19M | +4% | 1.1M | 18.16 |
|
| Nurix Therapeutics (NRIX) | 1.0 | $18M | 968k | 18.97 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.0 | $18M | +10% | 3.3M | 5.50 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.0 | $18M | -72% | 31k | 582.34 |
|
| Savara (SVRA) | 1.0 | $17M | +86% | 2.8M | 6.03 |
|
| Protagonist Therapeutics (PTGX) | 0.9 | $15M | -21% | 172k | 87.34 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.9 | $15M | -45% | 601k | 25.01 |
|
| Establishment Labs Holdings Ord (ESTA) | 0.8 | $15M | -35% | 200k | 72.88 |
|
| Erasca (ERAS) | 0.8 | $15M | -9% | 3.9M | 3.72 |
|
| Vera Therapeutics Cl A (VERA) | 0.7 | $13M | -17% | 250k | 50.64 |
|
| Cogent Biosciences (COGT) | 0.7 | $12M | NEW | 350k | 35.52 |
|
| Ovid Therapeutics (OVID) | 0.7 | $12M | +169% | 7.2M | 1.63 |
|
| Travere Therapeutics (TVTX) | 0.7 | $12M | -40% | 300k | 38.21 |
|
| Jade Biosciences Com New (JBIO) | 0.6 | $11M | +994% | 715k | 15.43 |
|
| Travere Therapeutics Note 2.250% 3/0 (Principal) | 0.6 | $10M | 7.0M | 1.43 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.5 | $9.6M | 275k | 35.08 |
|
|
| Celldex Therapeutics Com New (CLDX) | 0.5 | $9.5M | +16% | 350k | 27.16 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.5 | $9.5M | +42% | 1.8M | 5.24 |
|
| Tango Therapeutics (TNGX) | 0.5 | $8.9M | NEW | 1.0M | 8.86 |
|
| Sutro Biopharma Com Shs (STRO) | 0.5 | $8.7M | NEW | 748k | 11.57 |
|
| Revolution Medicines (RVMD) | 0.5 | $8.0M | 100k | 79.65 |
|
|
| Mbx Biosciences (MBX) | 0.4 | $7.9M | +51% | 250k | 31.54 |
|
| Miragen Therapeutics (VRDN) | 0.4 | $7.8M | 250k | 31.12 |
|
|
| Arcus Biosciences Incorporated (RCUS) | 0.4 | $7.1M | NEW | 300k | 23.83 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.4 | $6.8M | +228% | 1.1M | 5.92 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.4 | $6.5M | +464% | 890k | 7.36 |
|
| Celcuity Note 2.750% 8/0 (Principal) | 0.4 | $6.5M | 3.0M | 2.17 |
|
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.4 | $6.4M | NEW | 30k | 213.24 |
|
| Summit Therapeutics Put Option (SMMT) | 0.3 | $6.1M | 350k | 17.49 |
|
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.3 | $5.9M | NEW | 707k | 8.31 |
|
| Engene Holdings (ENGN) | 0.3 | $5.8M | +735% | 643k | 9.03 |
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.3 | $5.6M | 245k | 23.00 |
|
|
| Rezolute Com New (RZLT) | 0.3 | $5.5M | +11% | 2.4M | 2.36 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 0.3 | $5.4M | NEW | 250k | 21.55 |
|
| Eliem Therapeutics (CLYM) | 0.3 | $5.2M | 1.3M | 4.00 |
|
|
| Immunovant (IMVT) | 0.3 | $5.1M | -33% | 200k | 25.42 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.3 | $5.0M | -31% | 2.5M | 2.02 |
|
| Dianthus Therapeutics (DNTH) | 0.3 | $4.7M | -56% | 115k | 41.21 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.3 | $4.6M | NEW | 70k | 66.39 |
|
| Ibio Com New (IBIO) | 0.2 | $4.0M | NEW | 2.1M | 1.93 |
|
| Nextcure Com New (NXTC) | 0.2 | $3.5M | +28% | 247k | 14.19 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.2 | $3.5M | 75k | 46.55 |
|
|
| Belite Bio Sponsored Ads (BLTE) | 0.2 | $3.2M | NEW | 20k | 159.96 |
|
| Arrivent Biopharma (AVBP) | 0.2 | $3.0M | NEW | 150k | 20.12 |
|
| Mersana Therapeutics (MRSN) | 0.2 | $2.9M | NEW | 100k | 28.93 |
|
| Oaktree Acquisition Corp Iii Unit 10/04/2029 (OACCU) | 0.2 | $2.7M | 250k | 10.61 |
|
|
| Arbutus Biopharma Call Option (ABUS) | 0.1 | $2.5M | +146% | 522k | 4.81 |
|
| Anteris Technologies Global (AVR) | 0.1 | $2.4M | +8% | 487k | 4.99 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.1 | $2.4M | -21% | 573k | 4.15 |
|
| Eupraxia Pharmaceuticals (EPRX) | 0.1 | $2.3M | 300k | 7.55 |
|
|
| Geron Corporation (GERN) | 0.1 | $2.0M | 1.5M | 1.32 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 0.1 | $1.7M | NEW | 75k | 23.00 |
|
| Lenz Therapeutics Put Option (LENZ) | 0.1 | $1.6M | NEW | 100k | 16.00 |
|
| Kezar Life Sciences Com New (KZR) | 0.1 | $1.4M | NEW | 229k | 6.29 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.1 | $1.4M | 200k | 6.90 |
|
|
| Cogent Biosciences Note 1.625%11/1 (Principal) | 0.1 | $1.2M | NEW | 1.0M | 1.18 |
|
| Perspective Therapeutics Com New (CATX) | 0.0 | $825k | 300k | 2.75 |
|
|
| Macrogenics (MGNX) | 0.0 | $780k | NEW | 484k | 1.61 |
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.0 | $652k | -85% | 50k | 13.03 |
|
| X4 Pharmaceuticals Com New (XFOR) | 0.0 | $580k | NEW | 145k | 4.00 |
|
| Q32 Bio (QTTB) | 0.0 | $92k | 28k | 3.32 |
|
|
| Adagio Med Hldgs (ADGM) | 0.0 | $83k | 80k | 1.04 |
|
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $1.8k | 75k | 0.02 |
|
Past Filings by Affinity Asset Advisors
SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020
- Affinity Asset Advisors 2025 Q4 filed Feb. 13, 2026
- Affinity Asset Advisors 2025 Q3 filed Nov. 13, 2025
- Affinity Asset Advisors 2025 Q2 filed Aug. 13, 2025
- Affinity Asset Advisors 2025 Q1 filed May 14, 2025
- Affinity Asset Advisors 2024 Q4 filed Feb. 13, 2025
- Affinity Asset Advisors 2024 Q3 filed Nov. 13, 2024
- Affinity Asset Advisors 2024 Q2 filed Aug. 14, 2024
- Affinity Asset Advisors 2024 Q1 filed May 14, 2024
- Affinity Asset Advisors 2023 Q4 filed Feb. 13, 2024
- Affinity Asset Advisors 2023 Q3 filed Nov. 14, 2023
- Affinity Asset Advisors 2023 Q2 restated filed Aug. 21, 2023
- Affinity Asset Advisors 2023 Q2 filed Aug. 14, 2023
- Affinity Asset Advisors 2023 Q1 filed May 15, 2023
- Affinity Asset Advisors 2022 Q4 filed Feb. 13, 2023
- Affinity Asset Advisors 2022 Q3 filed Nov. 14, 2022
- Affinity Asset Advisors 2022 Q2 filed Aug. 12, 2022